Each 100 ml IV Infusion contains Mannitol 20 g.

Microtol Infusion contains Mannitol 20%, a hyperosmotic agent used to rapidly reduce intracranial pressure, manage cerebral edema, promote osmotic diuresis, and facilitate the urinary excretion of toxic substances. By increasing plasma osmolality, it draws water from tissues into the intravascular compartment, making it an effective therapy in neurosurgical, neurological, and renal care settings.

Microtol Infusion is indicated for the promotion of diuresis before irreversible renal failure becomes established, reduction of intracranial pressure, treatment of cerebral edema, and promotion of urinary excretion of toxic substances.

Mannitol is an osmotic diuretic that increases plasma osmolality, creating an osmotic gradient that promotes the movement of water from intracellular and interstitial compartments into the intravascular space. This effect reduces brain volume, cerebrospinal fluid pressure, and intracranial pressure, while increasing renal blood flow and urine output. The enhanced diuresis also facilitates the elimination of certain toxic substances through the kidneys.

For the reduction of intracranial pressure and brain mass: Adults: Administer 0.25–2 g/kg body weight as a 15–25% solution infused over 30–60 minutes. Children: Administer 1–2 g/kg body weight over 30–60 minutes, or as directed by the treating physician.

Microtol Infusion is contraindicated in patients with well-established anuria due to severe renal disease, severe pulmonary congestion or pulmonary edema, active intracranial bleeding (except during craniotomy), severe dehydration, progressive renal damage or dysfunction after initiation of mannitol therapy, progressive heart failure or pulmonary congestion following therapy, and in patients with known hypersensitivity to Mannitol.